Red Alert: Are We Overlooking Blood Transfusion Risks in Older Adults?
"New research questions the one-size-fits-all approach to blood transfusions, suggesting older adults may benefit from a more liberal strategy."
For years, restrictive blood transfusion strategies have been the gold standard in medical practice, aiming to conserve resources and minimize patient exposure to allogeneic blood. These guidelines, supported by numerous randomized controlled trials (RCTs), have shaped protocols worldwide. However, a critical question remains: are these strategies equally beneficial for all patient populations, particularly older adults?
A groundbreaking systematic review and meta-analysis of nine RCTs, focusing specifically on transfusion outcomes in older patients, challenges this assumption. Published in The Lancet Haematology, the study reveals that a more liberal transfusion strategy may lead to better outcomes in geriatric patients compared to the restrictive approaches currently recommended. This finding has significant implications for blood supply and demand, as well as the personalized care of an aging population.
With the global population rapidly aging, understanding the unique healthcare needs of older adults is more critical than ever. This article delves into the details of this meta-analysis, exploring its findings, implications, and the urgent need for further research to refine transfusion practices for geriatric patients.
A Common Therapy With Measurable Risk
The Red Cross reports that it provides about 40% of the nation's blood and blood components, all from volunteer donors. Red blood cell transfusions remain widespread in hospitals: the CRIT study found that anemia is common in critically ill patients and results in a large number of RBC transfusions. That study also reported that the number of RBC units transfused is an independent predictor of worse clinical outcome. Aggregate U.S. transfusion counts are tracked across 2015-2021 through the National Blood Collection and Utilization Survey. Similar utilization patterns are documented internationally, including among second- and third-level public hospitals in Turkey.
Hemoglobin Triggers and Lingering Controversy
Standard practice relies on transfusion triggers, with strict hemoglobin limits considered key to quality care because they help avoid risks and ensure resources are used wisely. This approach emphasizes tailoring each medical choice to the individual patient's needs. Even so, allogeneic transfusion of whole blood and fractionated components remains a controversial topic with respect to transfusion triggers and practices. Standardized, regulated management of blood transfusion is regarded as an important guarantee of transfusion safety. Debates persist about how tight those thresholds should be, with expert opinion favoring a more liberal approach in preterm neonates suggesting that liberal transfusion thresholds may favor improved neurodevelopmental outcomes.
From Animal Experiments to Lifesaving Therapy
Blood transfusion — transferring blood products into a person's circulation intravenously — has a deep and dramatic history. In 1665, physician Richard Lower performed the first recorded successful transfusion in England, keeping dogs alive by transfusing blood from other dogs. In 1818, James Blundell performed the first successful transfusion of human blood to treat postpartum hemorrhage. Over the following centuries, milestones such as blood typing, blood banking, and HIV screening transformed transfusion from a dangerous experiment into routine medical care. The story reaches back even further, with attempts attributed to Pope Innocent VIII in 1492 and later experiments in the late 1660s that promised renewed youth and vigor.
Challenging the Status Quo: What the Research Reveals
The meta-analysis, conducted by researchers from the University of the Sunshine Coast in Australia, scrutinized data from 5,780 patients across nine randomized controlled trials. These trials compared restrictive versus liberal transfusion strategies in adults aged 65 years and older, or in populations where a substantial proportion were over 65. The primary outcomes assessed were 30-day and 90-day mortality rates.
- Higher Mortality: Restrictive transfusion strategies were associated with increased 30-day and 90-day mortality rates in older adults.
- Cardiac Complications: Liberal transfusion strategies showed better outcomes in terms of composite cardiac complications.
- No Impact on Infections: Transfusion strategy did not significantly affect infection rates.
Refining When Transfusion Is Truly Needed
Recent research continues to refine when and how transfusions should be used. The Cochrane Database review on transfusion thresholds for guiding red blood cell transfusion remains a key reference in the field. In fetal medicine, new studies compare late versus early intrauterine blood transfusion in fetal anemia related to hemolytic disease of the fetus and newborn. Clinical teams increasingly watch transfusion levels closely and balance risks and benefits when deciding on hemoglobin-based triggers. Ongoing science coverage highlights continued breakthroughs in transfusion-related research and technology.
Persistent Risks Despite Vigilance
Despite being critical in medical care — replenishing blood during surgery or injury and assisting patients with blood production deficiencies — transfusions carry documented risks. Adverse events including transfusion-associated circulatory overload (TACO) and transfusion-associated dyspnoea have increased despite existing vigilance measures. Inappropriate and unnecessary transfusion, along with incorrect blood component transfusions due to human or laboratory errors, also remain persistent concerns. Transfusion-related immunomodulation (TRIM), the adverse effects of blood transfusion on the immune system, has been examined in many clinical trials, with controversial results across different clinical settings.
Restrictive vs. Liberal Strategies and Alternatives
The choice between restrictive and liberal transfusion strategies sits at the center of comparative research. Trials have compared liberal strategies with higher hemoglobin thresholds (such as ≤ 9 g/dL or ≤ 10 g/dL) against restrictive approaches, evaluating outcomes including mortality, myocardial infarction, stroke, number of units transfused, and adverse transfusion reactions. Cochrane reviews of transfusion thresholds have also compared patients exposed to blood transfusion across different clinical settings. The case for alternatives to allogeneic blood rests on the principle that transfusions carry inherent risks, associated costs, and affect the blood inventory available for health-care delivery. Systematic reviews continue to weigh transfusion against alternative treatment modalities in acute bleeding.
The Path Forward: Personalized Care and Further Research
The implications of this meta-analysis are far-reaching. As the global population ages, healthcare systems must adapt to meet the unique needs of older adults. The study underscores the importance of moving away from a one-size-fits-all approach and embracing personalized care strategies that consider the specific physiological characteristics of geriatric patients. Further research is needed to determine the optimal transfusion thresholds and strategies for older adults across various clinical specialties. This includes exploring the impact of underlying comorbidities, frailty, and individual patient conditions on transfusion outcomes. By tailoring transfusion practices to the unique needs of older adults, healthcare providers can potentially improve patient outcomes, optimize resource allocation, and enhance the quality of life for this vulnerable population.
Expert Opinion Meets Gaps in Evidence
Expert commentary frequently highlights how transfusion decisions can outpace the available evidence. In neonates with cancer who undergo radiotherapy, for instance, expert opinion recommends maintaining an Hb threshold of 4.5 mmol/L when they are between three and four weeks old, while acknowledging that no specific studies in this population were identified. Analyses of adverse transfusion reactions have pooled three randomized trials of acetaminophen and antihistamine premedication, covering 517 patients and 4,444 red blood cell or platelet transfusions. Clinicians also weigh the risk of occult blood loss when assessing the anemic trauma victim, with anticipated surgical blood loss guiding red cell use. Underlying all of this is a highly detailed understanding of compatibility, with the International Society of Blood Transfusion identifying 45 blood group systems comprising hundreds of antigens.
Market Growth and Evolving Practice
The transfusion landscape is projected to keep expanding. Market research forecasts that the blood transfusion device market will reach USD 7.27 billion by 2035, growing at a 4.05% compound annual growth rate. This mirrors five decades of advances in transfusion medicine that hematology organizations highlight as central to modern hematologic care. Practice itself continues to shift, with whole blood transfusion — involving all components including red blood cells, plasma, platelets, and clotting factors — recognized as indicated in life-threatening bleeding. These trends point toward a future of more accessible and more precisely targeted transfusion support.
Wide Variation and Enduring Challenges
Transfusion practice faces significant systemic challenges, beginning with wide variation in how it is delivered. Neonates and infants hospitalized in the neonatal intensive care nursery frequently require blood product transfusions, yet clinical practices vary widely. Even emergency protocols diverge: a survey of 46 pediatric massive transfusion protocols found definitions ranging from greater than 40 milliliters per kilogram in 2 hours to more than 50 percent of blood volume in 2 hours with continued need for transfusion. At the same time, transfusion remains a life-saving procedure integral to modern medicine that carries inherent risks, the most significant being transfusion reactions. The appeal of transfused blood is centuries old — in late-1660s Paris, transfusing the blood of calves and lambs into human veins held the promise of renewed youth and vigor.
From the Laboratory Bench to Everyday Care
Beyond the statistics, blood transfusion touches real patients every day. The procedure transfers blood or its components — such as red cells, plasma, or platelets — from a donor to a recipient, and is essential in treating blood loss from trauma, surgeries, or medical conditions like anemia. Real-world research continues to probe how the body responds, including a TRANSFUSION-REALITY sub-study examining the impact of red blood cell transfusion on platelet activation and aggregation using flow cytometry and light transmission aggregometry. Demand is constant, as many people are in need of donor blood every day around the world, with blood stations and specialists working to collect, preserve, and deliver it to those in need.